Brief: AIM Immunotech Signs Agreement For Planning Of A Proposed Phase 3 Clinical Trial Of Ampligen In The Treatment Of Late-Stage Pancreatic Cancer
02/03/2026 14:01
March 2 (Reuters) - AIM ImmunoTech Inc AIM.A: AIM IMMUNOTECH SIGNS AGREEMENT FOR PLANNING OF A PROPOSED PHASE 3 CLINICAL TRIAL OF AMPLIGEN IN THE TREATMENT OF LATE-STAGE PANCREATIC CANCER AIM IMMUNOTECH INC - SIGNS AGREEMENT WITH THERMO FISHER FOR PHASE 3 TRIAL OF AMPLIGEN Source text: ID:nGNXzn7Pq Further company coverage: AIM.A ((Reuters.Briefs@thomsonreuters.com;))
Recent news on AIM ImmunoTech
See all newsBrief: Aim Immunotech Duripanc Primary Endpoint Analysis To Begin December 2026 Topline Results Expected Q1 2027
Brief: Aim Immunotech Files To Offer And Resell Up To 13.08 Million Shares Of Common Stock By Selling Stockholders
Brief: AIM ImmunoTech Announces $2.65 Million Financing Priced At-Market Under NYSE American Rules
Brief: Aim Immunotech Announces Significant Increase In Stockholder Equity And Extension Of Promissory Note Maturity Date To June 2027
Brief: Aim Immunotech Announces 50% Objective Response Rate (Orr) In Upmc Recurrent Ovarian Cancer Phase 2 Clinical Trial, Suggesting Breakthrough Combination Potential